GSK Plc is planning five simultaneous late-stage trials for a cancer drug it hopes will be a blockbuster, as new Chief Executive Officer Luke Miels tries to revitalize a company not known for its risk-taking.
www.bloomberg.com
#GSK #CEO #Oncology #Rivals #Playbook #Search #Growth
Goldman Sachs Group Inc. blew through expectations for equities-trading revenue, netting an all-time Wall Street record of $4.31 billion in…
President Donald Trump announces Apple’s plan to invest another $100 billion on domestic manufacturing, the iPhone maker’s latest move to…
Oklo Inc. is planning a $1.68 billion first-of-its-kind facility in Tennessee that will convert nuclear waste into fuel to power…
